Project Grant R01CA290043
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$560K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $219,351.00 Project Grant with an award date of Feb 1, 2025 and an ultimate completion date of Jan 31, 2027 was provided by the National Cancer Institute under the Cancer Treatment Research Federal Grant Program (CFDA 93.395). The primary objective is to conduct preclinical research on the efficacy and toxicity of thyroid hormone T3 as a potential treatment for medulloblastoma, the most common malignant brain tumor in children. Specifically, the research will evaluate the toxicity,...
This federal Project Grant award of $399,709 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) aims to develop an EYA2 tyrosine phosphatase inhibitor as a novel therapeutic for medulloblastoma, the most common malignant brain tumor in children. The award, made to Sieyax, Inc., an SBA-certified woman-owned small business, supports preclinical studies to optimize the lead compound SD3-146 and evaluate its pharmacodynamics, pharmacokinetics, and...
The National Cancer Institute (NCI) awarded a $602,486 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Health Research, Inc., a not-for-profit research organization based in Buffalo, NY. The grant aims to explore the feasibility of targeting retrotransposons, or mobile genetic elements, as a novel approach to treating refractory pediatric cancers, with a primary focus on high-risk neuroblastoma. The project seeks to comprehensively characterize retrotransposon activity...
The Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $191,064.00 to the Sloan-Kettering Institute for Cancer Research for a Phase II clinical trial of the avutometinib plus defactinib combination therapy in treating two rare and aggressive forms of thyroid cancer - radioiodine-refractory (RAIR), recurrent and/or metastatic (R/M) differentiated thyroid cancer and anaplastic thyroid cancer. The award, starting on September 15, 2024, supports...
The National Cancer Institute (NCI) awarded a $600,079 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University to develop and evaluate a combination molecular radiotherapy approach for treating relapsed and refractory neuroblastoma. The project aims to deploy next-generation high linear energy transfer (LET) radiopharmaceuticals targeting the norepinephrine transporter (NET) and somatostatin receptor 2 (SSTR2) biomarkers, which are highly expressed in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $662,516 aims to investigate how fractionated radiation affects the tumor microenvironment to enhance drug delivery and improve the safety and efficacy of chemoradiotherapy for locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The key research objectives include: 1) Quantifying how local radiation reshapes the tumor microenvironment to influence...
The Project Grant award R01CA292508 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) is focused on advancing the understanding and treatment of cancers with mutations in the IDH1 gene. This $693,781 award to the General Hospital Corporation (Massachusetts General Hospital) for the period of April 14, 2025 to March 31, 2030 supports research to: Further study how mutant IDH1 causes cancer growth and how IDH1 inhibitor drugs block cancer...
The National Cancer Institute (NCI) awarded a $667,792 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Chicago. The five-year grant, running from June 1, 2024 to May 31, 2029, will fund research to develop "ultra-potent, pharmacologically stable" synthetic transcriptional repressors (STRs) that can directly inhibit the oncogenic activity of the transcription factors XBP1 and HIF1A. These targets are critical for the survival and growth of...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $678,879 to Cold Spring Harbor Laboratory to conduct research on epigenetic mechanisms that can re-establish tumor suppression in glioblastoma (GBM), the most common and deadly adult primary brain cancer. The key focus of the research is to define the epigenetic mechanism by which targeting the chromatin regulator BRD8 can re-activate the p53 tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,030,836 to The Children's Hospital Corporation (Boston Children's Hospital) to elucidate the molecular mechanisms underlying chemotherapy-induced neurotoxicity, with a focus on oxidative distress. The research aims to understand how the chemotherapeutic drug methotrexate causes damage to the choroid plexus and cerebrospinal fluid, leading to neurological impairments in pediatric...